Cancer News

Nipple-Sparing Mastectomy Has Low Rate of Breast Cancer Recurrence (08/01/2017)

Investigators say most women with breast cancer are eligible for this type of mastectomy, which leaves the natural nipple in place Women with breast cancer who undergo nipple-sparing mastectomy (NSM) have a low rate of the cancer returning within the first five years, when most recurrences in the breast are diagnosed, findings of a single-center …

Continue reading "Nipple-Sparing Mastectomy Has Low Rate of Breast Cancer Recurrence"

Balance and Gait is Negatively Impacted By Chemotherapy Treatment (07/26/2017)

A single chemotherapy treatment can result in a significant negative impact on walking gait and balance, putting patients at an increasing risk for falls, according to a new study involving breast cancer patients conducted by researchers at The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research …

Continue reading "Balance and Gait is Negatively Impacted By Chemotherapy Treatment"

FDA Approves Nerlynx for Treatment of Early Stage HER2-Positive Breast Cancer (07/18/2017)

The U.S. Food and Drug Administration approved Nerlynx (eratinib) for the extended adjuvant treatment of adult patients with early stage HER2-overexpressed/amplified breast cancer, to follow adjuvant trastuzumab-based therapy. Approval was based on the ExteNET trial (NCT00878709), a multicenter, randomized, double-blind, placebo-controlled trial of Nerlynx following adjuvant trastuzumab treatment. Women (n=2,840) with early-stage HER2-positive breast cancer …

Continue reading "FDA Approves Nerlynx for Treatment of Early Stage HER2-Positive Breast Cancer"

Immunotherapy with Checkpoint Inhibitor Durvalumab Show Promise in Triple Negative Breast Cancer (06/22/2017)

Doctors from Yale Cancer Center presented new data at the American Society of Clinical Oncology meeting on the impact of combining the immune checkpoint inhibitor (durvalumab/MEDI4736) with chemotherapy as preoperative treatment for early stage triple negative breast cancer (TNBC).  Overall patients with TNBC achieved a 71% pathologic complete response to the combination treatment in the …

Continue reading "Immunotherapy with Checkpoint Inhibitor Durvalumab Show Promise in Triple Negative Breast Cancer"

Shows Improved Outcomes with Addition of Keytruda® in Triple Negative High-Risk Breast Cancer (06/09/2017)

The results from the I-SPY 2 TRIAL investigating Keyytruda (pembrolizumab), in combination with standard therapy as a pre-operative (neoadjuvant) treatment for patients with locally advanced breast cancer were released at the 2017 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago.  The estimated pathologic complete response (pCR) rate increased nearly threefold in patients with triple-negative …

Continue reading "Shows Improved Outcomes with Addition of Keytruda® in Triple Negative High-Risk Breast Cancer"

FDA Approves First-of-its-kind Kisqali® Femara® Co-Pack For Initial Treatment Of HR+/HER2- Advanced or Metastatic Breast Cancer (05/31/2017)

The US Food and Drug Administration (FDA) has approved the Kisqali ®Femara ® Co-Pack (ribociclib tablets; letrozole tablets) for the treatment of hormone receptor-positive, human epidermal growth factor receptor-2 negative (HR+/HER2-) advanced or metastatic breast cancer in postmenopausal women 1. The Kisqali-Femara Co-Pack is the first, and only currently available, combination pack with two prescription products in advanced breast …

Continue reading "FDA Approves First-of-its-kind Kisqali® Femara® Co-Pack For Initial Treatment Of HR+/HER2- Advanced or Metastatic Breast Cancer"

Half of Breast Cancer Patients Pursue Reconstructive Surgery Without Understanding of Risks (05/16/2017)

More than half of breast cancer patients (57 percent) undergoing mastectomy lack the necessary medical knowledge to make a high-quality decision about reconstructive surgery that aligns with their personal goals, suggesting a trend toward overtreatment, according to a new study conducted by researchers at The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer …

Continue reading "Half of Breast Cancer Patients Pursue Reconstructive Surgery Without Understanding of Risks"

Breast cancer rates increasing among Asian Americans (04/17/2017)

Researchers examined breast cancer incidence rates among seven Asian American ethnic groups in this new study.  In contrast to other US racial/ethnic groups, Asian Americans have experienced steadily increasing breast cancer rates over the past 15 years. To better understand potential contributors to this increase, researchers at the Cancer Prevention Institute of California (CPIC) examined …

Continue reading "Breast cancer rates increasing among Asian Americans"

Tecentriq Plus Abraxane Results Suggest Novel Immunotherapy PD-1 “Checkpoint” Inhibitors Have Role in Management of Triple-Negative Breast Cancer (04/12/2017)

The investigative agent, Tecentriq (atezolizumb), in addition to the chemotherapy agent, Abraxane (nab-paclitaxel), provides high anti-cancer responses among patients with triple-negative breast cancer. Approximately 10-20% of breast cancers are referred to as triple-negative breast cancer (TNBC). These types of cancers are both hormone-negative and HER2-negative. Hormone-negative breast cancer refers to a type of breast cancer …

Continue reading "Tecentriq Plus Abraxane Results Suggest Novel Immunotherapy PD-1 “Checkpoint” Inhibitors Have Role in Management of Triple-Negative Breast Cancer"

Kisqali® Receives FDA Approval as First Line Treatment for HR+/HER2- Metastatic Breast Cancer (03/16/2017)

The US Food and Drug Administration (FDA) has approved the investigational drug Kisqali® (ribociclib, LEE011) for first line treatment of hormone receptor + HER 2- metastatic breast cancer because when combined with Femera (letrozole) the combination benefits all such women and leads to improved survival without cancer recurrence. The interim results from a large clinical …

Continue reading "Kisqali® Receives FDA Approval as First Line Treatment for HR+/HER2- Metastatic Breast Cancer"